96 results
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”). (ll) U.S. Real
8-K
EX-10.2
KPRX
Kiora Pharmaceuticals Inc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
on the Company’s behalf, any filing with the FINRA Corporate Financing Department pursuant to FINRA Rule 5110 with respect to the Placement and pay all filing
8-K
EX-10.1
gh3xykwlomca7k6c
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
b2r b1md7l49t9k
16 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:16pm
8-K
EX-99.1
43p3l29mk4z8
6 Nov 23
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6:05am
8-K
7bfq8igkkr o9b
20 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:01pm
8-K
EX-1.1
48vivbgmko
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-99.1
dl0y44k8abii85
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-4.3
sskv sf16f
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
8-K
EX-99.2
g9tqpc
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
424B1
tui4x7
2 Jun 23
Prospectus with pricing info
5:08pm